View More Recent Stories
-
Jefferies Downgrades Inari Medical Inc. (NARI) to Hold
-
BofA Securities Reiterates Buy Rating on Stryker (SYK)
-
Evercore ISI Reiterates Outperform Rating on Stryker (SYK)
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Oppenheimer Starts Penumbra (PEN) at Outperform
-
Off Wall Street initiates short recommendation for Penumbra (PEN)
-
Wells Fargo Upgrades Penumbra (PEN) to Overweight
-
Penumbra (PEN): New Late Breaking Data Show Patients Treated with Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays
-
Penumbra (PEN) PT Raised to $260 at Canaccord Genuity
-
Penumbra (PEN) PT Raised to $235 at Piper Sandler
-
Penumbra (PEN) PT Raised to $241 at Deutsche Bank
-
Penumbra (PEN) PT Lowered to $232 at BTIG
-
Penumbra, Inc. (PEN) Tops Q3 EPS by 16c, reiterates guidance
-
Needham Reiterates Hold Rating on Penumbra (PEN)
-
Penumbra (PEN) PT Raised to $225 at Piper Sandler
-
Penumbra (PEN) PT Raised to $235 at Canaccord Genuity
-
Penumbra (PEN) PT Raised to $244 at Baird
-
Wells Fargo Reiterates Equal Weight Rating on Penumbra (PEN)
-
Stifel Starts Penumbra (PEN) at Buy
-
Penumbra, Inc. (PEN) Announces $200M Share Buyback
-
Penumbra (PEN) PT Lowered to $200 at Piper Sandler
-
Penumbra (PEN) PT Lowered to $176 at Canaccord Genuity
-
Penumbra (PEN) PT Lowered to $205 at RBC Capital
-
Penumbra (PEN) PT Lowered to $187 at BTIG
-
Citi Downgrades Penumbra (PEN) to Neutral
-
Penumbra, Inc. (PEN) Tops Q2 EPS by 8c, cuts guidance
-
Penumbra (PEN) PT Lowered to $230 at Truist Securities
-
Penumbra (PEN) PT Lowered to $231 at Baird
-
Analyst weighs in on current investor sentiment in MedTech sector

